Please login to the form below

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Bristol Myers Squibb (BMS) and Exelixis also recently revealed new analyses from a phase 3 study of their Opdivo (nivolumab) and Cabometyx (cabozantinib) combination in first-line, advanced RCC. ... BMS/Exelixis’ combination treatment doubled median

Latest news

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

BMS/Exelixis’ combination treatment doubled median PFS compared to Sutent, and also demonstrated a 34% reduction in the risk of death compared to Pfizer’s drug. ... BMS and Exelixis are also seeking approvals with additional health authorities
BMS gains FDA approval for second Opdivo combo in kidney cancer

The US Food and Drug Administration (FDA) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Exelixis’ Cabometyx in renal cell carcinoma (RCC) – the most common type of ... The European Medicines Agency (EMA) has already
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

and Exelixis’ tyrosine kinase inhibitor Cabometyx (cabozantinib).
BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... BMS and Exelixis have already completed their
Merck gets first approval for MET inhibitor tepotinib in Japan

ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of trial failures, while GlaxoSmithKline/Exelixis’ also seem to have dropped their MET/VEGF inhibitor foretinib and

More from news
Approximately 6 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy. California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy. ... His familiarity with Exelixis and the biotech landscape should make for a seamless
Decibel Therapeutics expands leadership team

Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Frances Heller joins BMS senior management

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Principal Medical Writer: Varies on experience

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....